Articles by National Institute of Allergy and Infectious Diseases

Nanoparticle vaccine targets six flu strains and may need to be taken less than once a year

There is no known cause for this rare immune disorder and no evidence of person-to-person transmissivity

Research needed to propel mucosal vaccine development is a priority

Good safety profile may help MARV vaccine efficiently quell emergency outbreaks

NIAID experts offer perspective on next-generation approaches

The authors note that the epidemiologic pattern of the outbreak of monkeypox resembles that of the early cases of AIDS

The first-in-human, Phase 1 trial will assess the safety and protection of a universal influenza vaccine

Based on Phase 3 trial results, the vaccine was 94.1 percent efficacious in preventing symptomatic COVID-19

Global network to focus on spillover potential

NIH workshop attendees review capabilities, limits of SARS-CoV-2 serology testing